PMCB (PharmaCyte Biotech) Change In Other Working Capital : $0.00 Mil (TTM As of Oct. 2024)

View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech Change In Other Working Capital?

PharmaCyte Biotech's Change In Other Working Capital for the quarter that ended in Oct. 2024 was $0.00 Mil. It means PharmaCyte Biotech's Other Working Capital stayed the same from Jul. 2024 to Oct. 2024 .

PharmaCyte Biotech's Change In Other Working Capital for the fiscal year that ended in Apr. 2024 was $-0.00 Mil. It means PharmaCyte Biotech's Other Working Capital declined by $0.00 Mil from Apr. 2023 to Apr. 2024 .

PharmaCyte Biotech Change In Other Working Capital Historical Data

The historical data trend for PharmaCyte Biotech's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCyte Biotech Change In Other Working Capital Chart

PharmaCyte Biotech Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Change In Other Working Capital

Get a 7-Day Free Trial

PharmaCyte Biotech Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
Change In Other Working Capital	Get a 7-Day Free Trial															-	-	-	-	-

PharmaCyte Biotech Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

PharmaCyte Biotech Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCyte Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169

Website

https://pharmacyte.com

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Executives

Wayne Remell Walker	director	1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb	director	100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen	director	299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K	director
Carlos Trujillo	director, officer: CFO	8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner	director, officer: Chairman, CEO, Pres and GC	8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree	director, officer: Chief Science Officer	12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099